Sai Parenteral IPO Listing at 2.04% Premium at ₹400.00 Per Share
- April 2, 2026
- Posted by: Ekta Dhawan
- Category: IPO
Sai Parenteral IPO Listing Today: The Sai Parenteral IPO was subscribed 2.05 times at the time of its closing. In this subscription, qualified institutional buyers (QIBs) received 14.98 times, and non-institutional investors (NIIs) received 1.16 times. The retail quota of the issue was subscribed to 56.03%. Before delving deeper into the topic, go through the details of the Sai Parenteral IPO.
Sai Parenteral IPO
It is a bookbuilding issue IPO of ₹408.79 crore, the entire and fresh issue of 0.73 crore shares and an offer for sale of 0.32 crore shares. The issue will be listed on BSE and SME on its tentative listing date, 2nd April 2026. The Sai Parenteral’s IPO date is scheduled from 24th March 2026 to 27th March 2026. The face value of Sai Parenteral’s shares stands at ₹10 per share, and the IPO Issue price band is set at ₹372 to ₹392 per share
| IPO Allotment Date | 30th April 2026 |
| IPO Open Date | 24th April 2026 |
| IPO Close Date | 27th April 2026 |
| Refund Initiation | 1st April 2026 |
| Issue Size | 18,06,000 shares(agg. up to ₹22 Cr) |
| Face Value | ₹10 per share |
| Lot Size | 1,200 Shares |
| Issue Price | |
| Issue Type | Bookbuilding IPO |
| Listing At | BSE & SME |
| Listing Date | 2nd April 2026 |
Sai Parenteral Listing
On the NSE platforms, Sai Parenteral shares are listed at ₹400.00 per share, reflecting a 2.04% premium over the issue price of ₹392.00 per share, whereas on the BSE, they are listed at ₹405.00 per share, reflecting a 3.31% premium.
About Sai Parenteral Limited
Sai Parenteral’s Ltd. is a diversified pharmaceutical formulations company with expertise in research, development, and manufacturing. The company operates in two segments: Branded Generic Formulations and Contract Development and Manufacturing Organisation (CDMO) products and services for domestic and international markets. The product portfolio spans multiple therapeutic areas, including cardiovascular, neuropsychiatry, anti-diabetic, respiratory health, antibiotics, gastroenterology, vitamins, minerals and supplements (VMS), analgesics, and dermatology. Offerings are across dosage forms such as injectables, tablets, capsules, liquid orals, and ointments.
Sai Parenteral’s Limited Financials
The company’s financial analysis is essential before applying for Sai Parenteral’s IPO. See the table for Sai Parenteral’s Limited’s financials.
| Year Ended | 31st Dec 2025 (in cr.) | 31st March 2025 (in cr.) | 31st March 2024 (in cr.) | 31st March 2023 |
| Assets | 376.24 | 272.39 | 268.10 | 133.96 |
| Total Income | 89.43 | 163.74 | 155.18 | 97.03 |
| Profit After Tax | 7.76 | 14.43 | 8.42 | 4.38 |
| EBITDA | 16.24 | 39.44 | 31.70 | 17.64 |
| Net Worth | 209.37 | 95.78 | 76.40 | 31.49 |
| Reserves and Surplus | 188.84 | 80.36 | 61.30 | 24.34 |
| Total Borrowings | 76.07 | 93.95 | 118.79 | 68.35 |
Explanation
Sai Parenteral’s Limited’s revenue increased by 5%, from ₹10.99 crore in March 2024 to ₹14.17 crore in March 2025. Moreover, the company’s PAT increased by 4% from ₹2.39 crore in March 2024 to ₹2.52 crore in March 2025.
Recent Articles
Emiac Technologies IPO GMP: Day 1 IPO Live Updates
Emiac Technologies IPO Subscription Status Day 1
Sai Parenteral’s IPO GMP: Day 4 IPO Live Updates
